{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T07:30:00Z","timestamp":1768807800299,"version":"3.49.0"},"reference-count":15,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2014,2,11]],"date-time":"2014-02-11T00:00:00Z","timestamp":1392076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2014,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>This randomized, double\u2010blind, placebo\u2010controlled, two\u2010way crossover study aimed to assess the pharmacokinetic interactions between brivaracetam 100\u00a0mg\/day and a combination oral contraceptive (<jats:styled-content style=\"fixed-case\">OC<\/jats:styled-content>) containing 30\u00a0\u03bcg ethinylestradiol and 150\u00a0\u03bcg levonorgestrel. The study was performed in 28 healthy women over five 28\u2010day menstrual cycles: baseline (<jats:styled-content style=\"fixed-case\">OC<\/jats:styled-content>only), two treatment cycles with brivaracetam (50\u00a0mg b.i.d.) or placebo coadministered with<jats:styled-content style=\"fixed-case\">OC<\/jats:styled-content>separated by a wash\u2010out cycle (<jats:styled-content style=\"fixed-case\">OC<\/jats:styled-content>only), and a follow\u2010up cycle (<jats:styled-content style=\"fixed-case\">OC<\/jats:styled-content>only). The<jats:styled-content style=\"fixed-case\">OC<\/jats:styled-content>was administered on days 1\u201321 of each cycle, and brivaracetam or placebo on days 1\u201328 of the treatment cycles. Pharmacokinetics of ethinylestradiol and levonorgestrel were determined on day 20; brivaracetam morning trough levels on days 20 (with<jats:styled-content style=\"fixed-case\">OC<\/jats:styled-content>) and 29 (without<jats:styled-content style=\"fixed-case\">OC<\/jats:styled-content>) were compared. C<jats:sub>max<\/jats:sub>(maximum plasma concentration) and AUC (area under the plasma concentration versus time curve) ratios for brivaracetam versus placebo (90% confidence interval [<jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>]) were 0.96 (0.88\u20131.04) and 0.90 (0.86\u20130.95) for ethinylestradiol, and 0.95 (0.91\u20130.99) and 0.92 (0.88\u20130.97) for levonorgestrel, within predefined bioequivalence limits (0.80\u20131.25). Brivaracetam trough levels were similar on days 20 and 29 (ratio 1.08; 90%<jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>0.98\u20131.18). No differences in breakthrough bleeding were seen across the five cycles. It was concluded that there were no interactions between brivaracetam 100\u00a0mg\/day and the<jats:styled-content style=\"fixed-case\">OC<\/jats:styled-content>.<\/jats:p><jats:p>A PowerPoint slide summarizing this article is available for download in the Supporting Information section<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"doi\" xlink:href=\"10.1111\/epi.12535\/supinfo\">here<\/jats:ext-link>.<\/jats:p>","DOI":"10.1111\/epi.12535","type":"journal-article","created":{"date-parts":[[2014,2,12]],"date-time":"2014-02-12T10:36:40Z","timestamp":1392201400000},"source":"Crossref","is-referenced-by-count":39,"title":["Interaction between brivaracetam (100\u00a0mg\/day) and a combination oral contraceptive: A randomized, double\u2010blind, placebo\u2010controlled study"],"prefix":"10.1111","volume":"55","author":[{"given":"Armel","family":"Stockis","sequence":"first","affiliation":[{"name":"UCB Pharma Braine\u2010l'Alleud Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shikiko","family":"Watanabe","sequence":"additional","affiliation":[{"name":"UCB Pharma Braine\u2010l'Alleud Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Fauchoux","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Unit Biotrial Rennes France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,2,11]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm030913e"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181ec7f7f"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2012.03598.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12432"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03158.x"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02829.x"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.017129"},{"issue":"1","key":"e_1_2_7_9_1","first-page":"1.250","article-title":"Double\u2010blind, placebo\u2010controlled, single and multiple rising dose study of brivaracetam in healthy Japanese male subjects \u2010 influence of CYP2C19 genotype","volume":"12","author":"Stockis A","year":"2012","journal-title":"Epilepsy Curr"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.187"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.72.1.114"},{"key":"e_1_2_7_12_1","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S0026-895X(25)13356-7","article-title":"Oxidation of 17 alpha\u2010ethynylestradiol by human liver cytochrome P\u2010450","volume":"33","author":"Guengerich FP","year":"1988","journal-title":"Mol Pharmacol"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199528030-00003"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2007.11.012"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000344167.78102.f0"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01868.x"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fepi.12535","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/epi.12535","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T20:54:22Z","timestamp":1746132862000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/epi.12535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,11]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["10.1111\/epi.12535"],"URL":"https:\/\/doi.org\/10.1111\/epi.12535","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,11]]}}}